A Phase IB/II Study of Venetoclax (ABT-199) in Combination With Liposomal Vincristine in Patients With Relapsed or Refractory T-Cell or B-Cell Acute Lymphoblastic Leukemia
Volunteers
Health Professionals
What is the purpose of this trial?
This phase Ib/II clinical trial studies the side effects and best dose of venetoclax and how well it works when given together with vincristine liposomal in treating patients with T-cell or B-cell acute lymphoblastic leukemia that has come back or does not respond to treatment. Venetoclax may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as vincristine liposomal, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax together with vincristine liposomal may work better in treating patients with acute lymphoblastic leukemia.
- Trial withEastern Coop Onc Group-American College Radiology Imaging Netwk(ECOG-ACRIN)
- Ages18 years and older
- GenderBoth
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Amer Zeidan, MBBS
- Aron Flagg, MD
- Asher Marks, MD
- Claudia Auerbach, APRN
- Elan Gorshein, DO, JD, MPH
- Erin Medoff
- Farzana Pashankar, MD, MRCP, MBBS
- Juan Vasquez, MD
- Judith Carbonella
- Lourdes Mendez, MD, PhD
- Manoj M Pillai, MBBS
- Mary Jane Hogan, MD, MPH, FAAP
- Niketa C Shah, MD
- Prasanna Ananth, MD, MPH
- Rory Shallis, MD
- Rozalyn Levine Rodwin, MD
- Stephanie Halene, MD, Dr Med
- Stephanie Massaro, MD, MPH
- Stephanie Prozora, MD
- Thomas Prebet, MD, PhD
- Last Updated08/06/2024
- Study HIC#2000023819